Truveta’s Post

Exploring the link between drugs and microbiota: a growing imperative in precision medicine https://buff.ly/3tJStNd #Microbiome #PrecisionMedicine #DrugDiscovery #Biomarkers #Research #Innovation #Medicine #PrecisionHealth #Prevention

https://lnkd.in/e8RhGUNq The transformative potential of the new weight-loss drugs - twenty-two empirical predictions: these have the potential to be personally, socially, and economically transformative. #semaglutide #ozempic #novonordisk #elililly #health #predictions #obesity

💊 Why Drug Repurposing and Personalized Medicine are Game-Changers 🧬 Traditional drug development can take over a decade and cost upwards of $2.6 billion. This process is even more challenging for personalized medicine, especially for those with rare diseases. That’s why we’re focusing on combining drug repurposing and personalized medicine. This approach offers several key benefits: •⁠ ⁠Cheaper and Faster Treatments: By using existing medications, we can significantly reduce the time and cost required to bring new treatments to market. •⁠ ⁠Customized Therapies: Tailoring medicine to an individual’s genetic makeup creates more effective treatments with fewer side effects. Combining drug repurposing with personalized medicine allows us to match existing drugs to specific genetic profiles. This strategy not only speeds up the development process but also enhances treatment efficacy, providing new hope for patients with rare and complex diseases like STXBP1. These innovative approaches are transforming the treatment landscape, offering faster, cost-effective, and highly targeted therapies for those in need. Follow us to learn more about how we're leveraging these strategies to fight rare diseases. 🌟 #DrugRepurposing #PersonalizedMedicine #STXBP1 #RafasMoonshot #InnovativeMedicine

We are excited to share our paper titled "Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access", published in #CPTJournal. Since the introduction of CFTR modulators, significant global disparities have arisen, largely excluding the cystic fibrosis population in low to middle-income countries. We propose a PK enhancement strategy developed using physiologically-based pharmacokinetic (PBPK) modeling, to mitigate the high cost of treatment. The aim of this paper is to raise awareness of global monopoly concerns and provide a clinical practice strategy to effectively address the issue. See it here: https://lnkd.in/eNGKs74J #ASCPTJournalFamily #modeling #simulation #PBPK #CFTRmodulators #Medicationaccess #Healthinequities #PKenhancement

There is exciting news from Truveta concerning a large real-world observational, comparative analysis of the use of Mounjaro (tirzepatide) and Ozempic (semaglutide) for weight loss. The results provide more evidence to suggest that acting on multiple hormone receptors brings added benefits. In other words, being a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., Mounjaro) produces better outcomes than being a GLP-1 receptor agonist alone (e.g., Ozempic).  The GLP-1 chatter among the popular press, social media, investment community, and adjacent players in the healthcare ecosystem (e.g., MedTech companies) is on 🔥 🔥 🔥. I am curious: how will the language change, if at all, to acknowledge the benefits of acting on multiple hormone receptors? Will it change with Mounjaro and Zepbound? Will retatrutide force a tipping point once it is on the market by acting on a third hormone receptor? Does it matter? Please share your thoughts in the comments. "The analysis found that patients taking tirzepatide were significantly more likely to achieve weight loss" https://lnkd.in/gHsNuDKm.

Another important article exploring the need for integrating behavioural science as early as possible in the drug discovery and development process. Please leave a comment and let me know your thoughts on behavioural science - do you see it's place in pharma? https://lnkd.in/edUF7_z2

One of the most significant obstacles we face in pharmacogenomics testing is the need for more standardization in both the testing procedures and the interpretation of results. We talk about pharmacogenomics and precision medicine below 👇 . https://lnkd.in/deapRV_V #pharmacogenomics #precisionmedicine #healthcare #drugsafety

It is inspiring to witness how AI is unlocking the potential of GLP-1s, offering transformative personalized care beyond diabetes care and weight loss. Despite high demand for GLP-1s like Wegovy, navigating treatment plans and finding specialized providers remains challenging. AI’s robust data analysis can personalize treatment plans, identify ideal GLP-1 candidates, locate specialized providers, and find pharmacies with these medications in stock. Additionally, AI can manage metabolic diseases through continuous glucose monitors, enhancing diabetes care and provide personalized weight loss recommendations. As research progresses, AI may also reveal new therapeutic potentials for GLP-1s in treating conditions like Parkinson's and Alzheimer's. Embracing these innovations transforms scientific discovery into enhanced patient experiences and outcomes. This exploration by Tina Reed highlights how weight loss drugs could become a pivotal test case for AI in healthcare. #AIinHealthcare #PatientOutcomes #PatientExperience #PersonalizedMedicine #HealthcareInnovation

Recent research highlights a significant side effect of popular weight loss drugs, Ozempic and Wegovy. The study indicates an association between these drugs and a rare form of vision loss called non-arteritic anterior ischemic optic neuropathy (NAION). Key Points: The study found that patients taking Ozempic and Wegovy have an increased risk of developing NAION, a condition that can lead to permanent vision loss. It is crucial for patients and healthcare providers to be aware of this potential risk and monitor for any signs of vision problems. Ongoing studies are needed to fully understand the extent of this risk and to develop guidelines for safer use of these medications. https://lnkd.in/eY8VEs8H via @statnews #Health #Research #Ozempic #Wegovy #VisionLoss #MedicalNews

Are you new to Advanced Therapy Medicinal Products (ATMPs) or are you just looking to deepen your knowledge? 🧬✨ Dive into our latest article that answers 7 key questions to give you a clear understanding of this innovative field within the European context.   👓 Read the article now: https://lnkd.in/e4tMrrVw   #JOIN4ATMP #ATMPs #Healthcare #GeneTherapy #CellTherapy #EUHealthcare #Learning